Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Nov 8.
Published before final editing as: Eur J Vasc Endovasc Surg. 2026 Jul 22:S1078-5884(26)00721-5. doi: 10.1016/j.ejvs.2026.07.042

Treating More Than One Tibial Arteries in Patients with Chronic Limb Threatening Ischaemia is Associated with Fewer Major Re-interventions*

Matthew T Menard a, Jeffrey J Siracuse b, Kenneth Rosenfield c, Michael S Conte d, Andres Schanzer e, Gheorge Doros b, Michael B Strong b, Maarit Venermo f, Mahmoud Malas g, Alik Farber b,*
PMCID: PMC13744166  NIHMSID: NIHMS2219167  PMID: 42486324

Abstract

Objective:

It is unclear whether treating multiple diseased tibial arteries at initial revascularisation improves outcomes with chronic limb threatening ischaemia (CLTI). Using data from the Best Endovascular versus Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial this study aimed to compare single arterial intervention (SAI) with multiple arterial intervention (MAI) for infrapopliteal disease.

Methods:

A retrospective, as treated analysis of the endovascular dataset from the BEST-CLI trial was undertaken to compare SAI with MAI. Only patients with multiple tibial vessel arterial occlusive disease with > 50% stenosis were included. Evaluated outcomes included major re-interventions (new bypass, interposition graft, thrombectomy, or thrombolysis), major adverse limb events (MALE)/death, and above ankle amputations. Risk adjusted analysis was performed.

Results:

There were 324 patients included: 224 SAI and 100 MAI. On unadjusted analysis at 3 years, SAI had a higher rate of a major re-intervention (19.2% vs. 5.3%; p = .010) and MALE/death (56.4% vs. 43.6%; p = .030), while there was no difference for above ankle amputation (19.7% vs. 13.1%; p = .14), amputation/death (45.2% vs. 43%; p = .53), or all cause death (37.7% vs. 33.5%, p = .57). SAI and MAI were associated with similar rates of resolution of initial CLTI symptoms (75.9% vs. 86%; p = .60). On risk adjusted analysis, SAI was associated with a higher rate of major re-intervention (odds ratio [OR] 3.14, 95% confidence interval [CI] 1.2 – 8.2; p = .019) than MAI; however, there was no increase in any re-intervention (OR 0.95, 95% CI 0.6 – 1.49; p = .80), MALE/death (OR 1.27, 95% CI 0.86 – 1.89; p = .24), above ankle amputation (OR 1.53, 95% CI 0.74 – 3.19; p = .25), initial CLTI resolution (OR 1.16, 95% CI 0.85 – 1.59; p = .36), or death (OR 1.03, 95% CI 0.64 – 1.63; p = .90).

Conclusion:

In patients with diffuse tibial arterial occlusive disease, treatment of multiple tibial arteries rather than just one at the time of index revascularisation was associated with fewer major re-interventions and should be considered.

Keywords: Amputation, Endovascular, Ischaemia

INTRODUCTION

Endovascular interventions have become increasingly common and are often used as first line interventions in many centres for patients with peripheral artery disease presenting with chronic limb threat ischaemia (CLTI).1–4 This trend also applies to infrapopliteal/tibial interventions. The Best Endovascular versus Best Surgical Therapy in Patients with CLTI (BEST-CLI) trial demonstrated that single segment great saphenous vein use was associated with improved major adverse limb event (MALE) free survival in patients with infrainguinal CLTI.4 Further, in a subgroup analysis of patients with infrapopliteal disease, bypass with single segment great saphenous vein was associated with lower MALE/death and major amputations.4,5 Despite this, there are still cases where endovascular tibial interventions are commonly performed, given endovascular bias, typically in patients who are unfit for open bypass and/or in those with an inadequate single segment great saphenous vein. Such patients are complex as they often have concurrent comorbidities and may have advanced tissue loss.6–8

In patients with diffuse, severe infrapopliteal disease, there has been a longstanding question as to whether treating multiple rather than a single diseased tibial artery at the time of initial revascularisation improves outcomes. There are conflicting published data with differing outcomes on the topic and most of these analyses use single centre, retrospective data, with variable outcomes reported.9–14

This study aimed to perform a retrospective analysis of prospectively collected data from the BEST-CLI trial, which included details on degree of stenosis per vessel treated, and compared single arterial intervention (SAI) with multiple arterial intervention (MAI) in patients with CLTI and severe infrapopliteal disease involving more than one infrapopliteal artery.

METHODS

The BEST-CLI trial (NCT02060630) was a multicentre, international, prospective, randomised controlled trial comparing infrainguinal bypass and endovascular therapy for patients with CLTI, and has previously been described.4 Both the need and the approach taken for the randomised intervention in this trial were determined by the treating investigator. The primary trial endpoint was MALE and/or all cause death and all first major re-interventions were independently adjudicated. Major re-interventions were defined as new bypass, interposition graft, thrombectomy, or thrombolysis. MALE was defined as a major re-intervention or an above ankle amputation. Initial CLTI resolution was defined as resolved symptoms of the presenting ischaemic rest pain and/or healing of the presenting wounds following index revascularisation. All patients were consented for inclusion in the trial and this was approved by the local institutional review board.

The as treated endovascular dataset from the BEST-CLI trial was analysed for this study. Infrapopliteal vessels (anterior tibial, posterior tibial, and peroneal arteries) were classified as having significant stenosis if there was ≥ 50% stenosis or an occlusion was noted. This analysis comparing SAI and MAI only included patients with multiple tibial arteries that had severe stenosis. Outcomes evaluated included major re-interventions, MALE/death, and above ankle amputations. As in the parent BEST-CLI trial, major re-interventions were defined as new bypass, interposition graft, thrombectomy, or thrombolysis. MALE was defined as a major re-intervention or an above ankle amputation. Risk adjusted analysis was performed using age, wound, ischemia, foot infection (WIfI) stage, smoking status, diabetes mellitus, statin use, anticoagulation, end stage renal disease (ESRD), concurrent femoropopliteal (FP) interventions, and history of prior infrainguinal revascularisation.

Characteristics were recorded as mean ± SD for continuous and proportions for categorical variables. Analysed variables included age, sex, congestive heart failure, chronic obstructive pulmonary disease, current smoking, chronic kidney disease, ESRD, diabetes mellitus, hypertension, previous myocardial infarction, coronary artery disease, prior stroke, medications, and symptoms. Limb and operative details were also recorded.

Continuous variables were compared using Student t tests. A univariate linear regression model was fitted for each baseline characteristic. Parameter estimates with 95% confidence intervals (CI) are presented. For each analysis, p < .050 was considered statistically significant. SAS version 9.4 (SAS Institute, Cary, NC, USA) software was used to conduct the statistical analyses.

RESULTS

Overall, 717 patients receiving endovascular procedures were considered for inclusion. Infrapopliteal arteries had ≥ 50% stenosis in one tibial vessel in 24.4%, two vessels in 35.3%, and three vessels in 40.3% of patients. The FP segment was concurrently treated in 74.9%. There were 84 limbs with two stenotic vessels and one treated, 29 limbs with two stenotic vessels and two treated, 58 limbs with three stenotic vessels and two treated, and 11 limbs with three stenotic vessels and three treated. These were grouped into limbs treated using single arterial intervention (SAI) and those treated using multiple arterial interventions (MAI). Patients with no interventions, interventions in vessels with < 50% stenosis, or with only one infrapopliteal vessel with > 50% stenosis were excluded (Fig. 1).

Figure 1.

Figure 1.

Distribution of multiple arterial (red) and single arterial interventions (blue). Patients excluded from the analysis are designated in grey.

There were 324 patients and limbs included: 224 SAI and 100 MAI. SAI patients more often had hyperlipidaemia and were on anticoagulation (Table 1). For these infrapopliteal interventions, atherectomy was used in 2.5%, drug coated balloons in 3.1%, and drug eluting stents in 5.6% of cases.

Table 1.

Patient characteristics comparing single (SAI) and multiple arterial tibial interventions (MAI) (n = 324).

Characteristic Total (n = 324) SAI (n = 224) MAI (n = 100) p value
Age – y 67.7 (10.76) 68.2 (11.38) 66.7 (9.19) .11
Sex – men 238 (73.5) 165 (73.7) 73 (73) .9
BMI – kg/m2 28.2 (6.2) 28.3 (5.95) 28.1 (6.74) .47
Hyperlipidaemia 223 (68.8) 163 (72.8) 60 (60) .022
Diabetes 260 (80.2) 182 (81.3) 78 (78) .50
Current smoking 67 (20.7) 46 (20.5) 21 (21) .92
Coronary artery disease 167 (51.5) 122 (54.5) 45 (45) .12
Heart failure 24 (7.4) 18 (8.0) 6 (6) .52
History of stroke 39 (12) 26 (11.6) 13 (13) .72
COPD 36 (11.1) 25 (11.2) 11 (11) .97
End stage renal disease 47 (14.6) 29 (12.9) 18 (18.2) .22
Statin 227 (70.1) 160 (71.4) 67 (67) .42
Aspirin 224 (69.1) 157 (70.1) 67 (67) .58
Clopidogrel 79 (24.4) 52 (23.2) 27 (27) .46
Direct oral anticoagulant 14 (4.3) 12 (5.4) 2 (2) .17
Warfarin 20 (6.2) 18 (8.0) 2 (2) .037
Prior ipsilateral revascularisation 23 (7.1) 20 (8.9) 3 (3) .055
Ankle brachial index 0.7 (0.37) 0.7 (0.34) 0.7 (0.43) .24
WIfI wound grade 0 34 (10.8) 21 (9.6) 13 (13.5) .43
WIfI wound grade 1 136 (43.2) 99 (45.2) 37 (38.5)
WIfI wound grade 2 120 (38.1) 84 (38.4) 36 (37.5)
WIfI wound grade 3 25 (7.9) 15 (6.8) 10 (10.4)
WIfI stage 0 13 (4.9) 8 (4.1) 5 (6.7) .35
WIfI stage 1 47 (17.5) 38 (19.7) 9 (12.0)
WIfI stage 2 84 (31.3) 57 (29.5) 27 (36.0)
WIfI stage 3 124 (46.3) 90 (46.6) 34 (45.3)

Data are presented as mean (standard deviation) or n (%). SAI = single artery intervention; MAI = multiple artery interventions; BMI = body mass index; COPD = chronic obstructive pulmonary disease; WIfI = wound, ischemia, foot infection.

On unadjusted analysis at 3 years, SAI was associated with a higher rate of a major re-intervention (19.2% vs. 5.3%; p = .010) and MALE/death (56.4% vs. 43.6%; p = .030), while there was no difference for above ankle amputation (19.7% vs. 13.1%; p = .14), amputation/death (45.2% vs. 43%; p = .53), or all cause death (37.7% vs. 33.5%; p = .57) (Table 2) (Fig. 2 – 4). A similar proportion of patients achieved resolution of initial CLTI symptoms (75.9% vs. 86%; p = .60) after SAI and MAI. On risk adjusted analysis, SAI compared with MAI was associated with a higher rate of major re-intervention (OR 3.14, 95% 1.2 – 8.2; p = .019); however, there was no increase in any re-intervention (minor or major) (OR 0.95, 95% CI 0.6 – 1.49; p = .80), MALE/death (OR 1.27, 95% CI 0.86 – 1.89; p = .24), above ankle amputation (OR 1.53, 95% 0.74 – 3.19; p = .25), initial CLTI resolution (OR 1.16, 95% CI 0.85 – 1.59; p = .36), or death (OR 1.03, 95% 0.64 – 1.63; p = .92) (Table 3).

Table 2.

Unadjusted 3 year Kaplan–Meier outcomes comparing single (SAI) and multiple arterial tibial interventions (MAI) (n = 324).

Endpoints – 3 y All patients (n = 324) SAI (n = 224) MAI (n = 100) p value
All cause death 36.3 37.7 33.5 .57
Above ankle amputation 17.6 19.7 13.1 .14
Major re-intervention 14.7 19.2 5.3 .010
Amputation/death 44.5 45.2 43 .53
MALE/death 52.9 56.4 43.6 .030

Data are presented as percentages. SAI = single artery intervention; MAI = multiple artery intervention; MALE = major adverse limb event.

Figure 2.

Figure 2.

Cumulative Kaplan–Meier estimate of the effect of single (SAI) and multiple (MAI) arterial interventions on major re-intervention.

Figure 4.

Figure 4.

Cumulative Kaplan–Meier estimate of the effect of single (SAI) and multiple (MAI) arterial interventions on major amputation.

Table 3.

Risk adjusted analysis.

Outcome Major re-intervention Major amputation All re-interventions CLTI resolution Death MALE/death
Age – y 0.99 (0.96–1.02); .43 0.99 (0.96–1.02); .41 1.01 (0.99–1.03); .26 1.00 (0.99–1.01); .98 1.02 (0.99–1.04); .18 1 (0.98–1.02); .88
Anticoagulant use 0.52 (0.15–1.85); .31 1.65 (0.62–4.37); .31 0.73 (0.35–1.51); .40 0.74 (0.45–1.20); .22 2.35 (1.28–4.3); .006 1.82 (1.06–3.1); .030
Cohort 2 1.67 (0.79–3.5); .18 1.36 (0.64–2.9); .43 1.17 (0.71–1.91); .54 1.00 (0.70–1.43); .99 0.59 (0.31–1.15); .12 1.04 (0.65–1.65); .88
Diabetes 0.59 (0.27–1.29); .19 2.79 (0.93–8.38); .067 0.69 (0.42–1.14); .15 0.88 (0.60–1.29); .51 1.13 (0.65–1.98); .66 1.28 (0.79–2.07); .32
ESRD 0.40 (0.09–1.69); .21 3.18 (1.59–6.38); .001 1.17 (0.62–2.19); .63 0.81 (0.52–1.27); .36 3 (1.82; 5.02); <.001 1.92 (1.22–3.03); .005
Concurrent FP 0.6 (0.29–1.22); .16 1.02 (0.53–1.96); .96 1.22 (0.75–1.99); .42 0.97 (0.70–1.35); .87 1.26 (0.78–2.01); .34 0.99 (0.67–1.45); .95
SAI vs. MAI 3.14 (1.2–8.19); .019 1.53 (0.74–3.19); .25 0.95 (0.60–1.49); .82 1.16 (0.85–1.59); .36 1.03 (0.64–1.63); .92 1.27 (0.86–1.89); .24
Prior infrainguinal revascularisation 1.11 (0.39–3.2); .85 0.78 (0.24–2.57); .68 1.53 (0.80–2.92); .20 1.28 (0.76–2.15); .35 0.71 (0.29–1.77); .47 1.1 (0.61–2.01); .75
Smoking >1 y 0.92 (0.4–2.12); .85 0.78 (0.38–1.59); .49 0.87 (0.53–1.45); .60 1.43 (1.00–2.04); .050 1.08 (0.65–1.79); .78 0.91 (0.6–1.38); .67
Smoking 2 wks–1 y 2 (0.65–6.16); .23 0.57 (0.12–2.6); .47 1.47 (0.67–3.23); .34 1.32 (0.70–2.47); .39 1.91 (0.8–4.56); .15 1.53 (0.76–3.07); .23
Smoking – current 1.15 (0.45–2.96); .77 1.55 (0.69–3.5); .29 1.27 (0.71–2.28); .42 1.36 (0.90–2.04); .15 1.02 (0.54–1.94); .95 1.17 (0.71–1.94); .54
Statin use 1.18 (0.54–2.58); .68 1.34 (0.65–2.75); .43 1.35 (0.85–2.16); .21 0.73 (0.53–1.00); .050 0.79 (0.52–1.21); .29 0.95 (0.65–1.38); .79
WIfI stage 3 0.97 (0.43–2.19); .95 1.35 (0.52–3.47); .54 0.71 (0.41–1.23); .23 0.90 (0.61–1.31); .58 0.94 (0.53–1.68); .84 0.97 (0.6–1.57); .89
WIfI stage 4 0.72 (0.31–1.65); .44 1.96 (0.82–4.73); .13 0.94 (0.57–1.55); .80 0.73 (0.51–1.04); .080 1.02 (0.58–1.81); .94 1.23 (0.78–1.94); .38

Data are presented as hazard ratio (95% confidence interval) and p value in each column. SAI = single artery intervention; MAI = multiple artery intervention; ESRD = end stage renal disease; FP = femoropopliteal intervention; WIfI = wound, ischaemia, foot infection.

DISCUSSION

This analysis showed that in patients with peripheral artery disease and severe stenosis in multiple tibial vessels, treatment of more than one tibial arteries was associated with fewer major re-interventions. More aggressive treatment did not lead to improved limb salvage or MALE free survival. This analysis provides additional evidence to an area of CLTI treatment where there has been a wide range of practice patterns with little data to guide choice of interventions.

A prior prospective randomised trial analysed 78 patients with CLTI and tissue loss undergoing 80 interventions, comparing treatment of more than one tibial artery with treatment of one alone. These patients were randomised after the first successful intervention, and the FP segment was concomitantly treated in 38.8%. In this report, multiple tibial arteries being treated was associated with higher contrast volume and radiation exposure. Multiple arterial interventions were also associated with quicker and improved overall wound healing and trended towards improved limb salvage.9

There have been single centre analyses examining whether treating additional tibial arteries affects outcomes. A retrospective review of 558 successful infrapopliteal endovascular arterial interventions for CLTI, 86% of which involved tissue loss, consisted of 90% single artery interventions and 10% multiple tibial interventions. Patients undergoing a single vessel intervention were more likely to have had a previous open or endovascular ipsilateral intervention. There were no differences in unadjusted or adjusted 1 year rates of re-intervention, major amputation, or re-stenosis for whether single or multiple infrapopliteal arteries were treated.10 Another retrospective single centre analysis from 2007 – 2015 examined 137 limbs in 123 patients with CLTI. These limbs had stenotic lesions in both the anterior and posterior tibial arteries. There were 84 limbs that had a single artery revascularised and 53 limbs with both the anterior and posterior tibial arteries treated. Patients who had multiple arteries treated had improved wound healing, shorter time to healing, and fewer re-interventions.11 However, another single centre, retrospective analysis examined 527 limbs in 470 patients with CLTI, with 46% single and 54% multiple arteries treated. This analysis found that there was no significant difference in freedom from amputation between the two strategies in both unadjusted and risk adjusted analyses. Unlike the current analysis, there was also no difference in the re-intervention rate. However, similar to this analysis, ESRD was associated with higher risk of amputation.12 In fact, ESRD was a risk factor for multiple outcomes in this analysis. This is consistent with prior analysis of CLTI patients, which showed that ESRD is consistently the leading risk factor for poor outcomes.13–16 This is despite the observation that patients with ESRD in the BEST-CLI trial were observed to have better outcomes with endovascular therapy.17

There were multiple limitations to this analysis. It was a retrospective analysis of prospectively collected data. There was bias both at the interventionalist and patient level as to who was offered single vs. multiple interventions. Angiograms were not yet available and therefore outcomes related to angiosomes, which has been shown to be associated with improved outcomes, could not be analysed.18–21 The extent of intervention in each tibial vessel was unclear. The MALE/death and above ankle amputation outcomes may have been underpowered and the lack of significance should be interpreted accordingly. The study was unable to assess whether the interventionalist determined whether it was unnecessary to intervene on additional vessels or if these vessels were attempted to be treated and it was not possible.

Conclusion

Treating multiple tibial arteries instead of a single tibial artery at the time of index revascularisation when multiple infrapopliteal vessels had significant stenosis or occlusion was associated with fewer major interventions. More investigation is needed to determine which patients with multitibial involvement are most appropriate for concomitant treatment of more than one tibial artery at the time of initial endovascular revascularisation.

Figure 3.

Figure 3.

Cumulative Kaplan–Meier estimate of the effect of single (SAI) and multiple (MAI) arterial interventions on major adverse limb events (MALE)/death.

WHAT THIS PAPER ADDS.

This secondary analysis of data from a prospective, randomised clinical trial examined treating multiple diseased tibial arteries compared with just one at the time of initial revascularisation for chronic limb threatening ischaemia. In patients with diffuse tibial arterial occlusive disease, treatment of multiple tibial arteries rather than just one at the time of index revascularisation was associated with fewer major re-interventions and should be considered.

FUNDING

To BEST-CLI trial during follow up period (2019 – 2021). BEST CLI Trial - NHLBI/NIH U01HL107407, U01HL107352, and U01HL115662 – trial coordination, analysis, Novo Nordisk Foundation for secondary analysis.

Physician Societies: Vascular InterVentional Advances (VIVA), Society for Vascular Surgery, New England Society for Vascular Surgery, Western Vascular Society, Eastern Vascular Society, Midwest Vascular Surgery Society, Southern Association of Vascular Surgeons, Canadian Society for Vascular Surgery, Society for Clinical Vascular Surgery, Society of Interventional Radiology, Vascular and Endovascular Surgery Society, Society for Vascular Medicine

Industry sources: Janssen, Gore, Bard, Medtronic, Cook, Boston Scientific, Abbott, Cordis, Cardiovascular Systems Inc.

CONFLICT OF INTEREST

J.S.: education grant WL Gore and BD. M.M.: Janssen scientific advisory board. M.C.: Abbott Vascular DSMB. M.V.: member, Scientific Advisory Board: IsoMab. K.R.: member of the Scientific Advisory Board or Consultant for Abbott Vascular, Access Vascular, Boston Scientific-BTG, Volcano-Philips, Surmodics, Cruzar Systems, Magneto, Summa Therapeutics, and University of Maryland; an unpaid member of the Scientific Advisory Board of Thrombolex, Inc; received grants from NIH and Boston Scientific; has equity from Access Vascular, Accolade, Contego, Endospan, Embolitech, Eximo, JanaCare, PQ Bypass, Primacea, MD Insider, Shockwave, Silk Road, Summa Therapeutics, Cruzar Systems, Capture Vascular, Magneto, Micell, and Valcare; and is a board member of VIVA Physicians, a not-for-profit 501c3, and National PERT Consortium, a not for profit 501c3. A.F.: Novo Nordisk Foundation, Grant recipient; Sanifit, Consultant; LeMaitre, Consultant; BioGenCell, 11 Consultant; Dialysis-X, Advisory Board; iThera Medical, Advisory Board.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

*

Presented as a plenary oral podium presentation at the European Society for Vascular Surgery, Istanbul, Turkey, September 2025.

REFERENCES

  • 1.Gallagher KA, Meltzer AJ, Ravin RA, Graham A, Shrikhande G, Connolly PH, et al. Endovascular management as first therapy for chronic total occlusion of the lower extremity arteries: comparison of balloon angioplasty, stenting, and directional atherectomy. J Endovasc Ther 2011;18:624–37. [DOI] [PubMed] [Google Scholar]
  • 2.Siracuse JJ, Menard MT, Eslami MH, Kalish JA, Robinson WP, Eberhardt RT, et al. Comparison of open and endovascular treatment of patients with critical limb ischemia in the Vascular Quality Initiative. J Vasc Surg 2016;63:958–65.e1. [DOI] [PubMed] [Google Scholar]
  • 3.Farber A, Menard MT, Conte MS, Kaufman JA, Powell RJ, Choudhry NK, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med 2022;387:2305–16. [DOI] [PubMed] [Google Scholar]
  • 4.Farber A, Menard MT, Conte MS, Rosenfield K, Hicks CW, Doros G, et al. Editor’s Choice – bypass after failed endovascular intervention is associated with an increased risk of above ankle amputation among patients with chronic limb threatening ischaemia in a randomised trial population. Eur J Vasc Endovasc Surg 2025;70:107–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Giles KA, Farber A, Menard MT, Conte MS, Nolan BW, Siracuse JJ, et al. Surgery or endovascular therapy for patients with chronic limb-threatening ischemia requiring infrapopliteal interventions. J Vasc Surg 2024;80:1515–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Saqib NU, Domenick N, Cho JS, Marone L, Leers S, Makaroun MS, et al. Predictors and outcomes of restenosis following tibial artery endovascular interventions for critical limb ischemia. J Vasc Surg 2013;57:692–9. [DOI] [PubMed] [Google Scholar]
  • 7.Almasri J, Adusumalli J, Asi N, Lakis S, Alsawas M, Prokop LJ, et al. A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 2019;58:S110–9. [DOI] [PubMed] [Google Scholar]
  • 8.Popplewell MA, Meecham L, Davies HOB, Kelly L, Ellis T, Bate GR, et al. Bypass versus Angioplasty for Severe Ischaemia of the Leg (BASIL) prospective cohort study and the generalisability of the BASIL-2 randomised controlled trial. Eur J Vasc Endovasc Surg 2024;67:146–52. [DOI] [PubMed] [Google Scholar]
  • 9.Biagioni RB, Biagioni LC, Nasser F, Burihan MC, Ingrund JC, Neser A, et al. Infrapopliteal angioplasty of one or more than one artery for critical limb ischaemia: a randomised clinical trial. Eur J Vasc Endovasc Surg 2018;55:518–27. [DOI] [PubMed] [Google Scholar]
  • 10.Darling JD, McCallum JC, Soden PA, Hon JJ, Guzman RJ, Wyers MC, et al. Clinical results of single-vessel versus multiple-vessel infrapopliteal intervention. J Vasc Surg 2016;64:1675–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kobayashi N, Hirano K, Yamawaki M, Araki M, Takimura H, Sakamoto Y, et al. Clinical effects of single or double tibial artery revascularization in critical limb ischemia patients with tissue loss. J Vasc Surg 2017;65:744–53. [DOI] [PubMed] [Google Scholar]
  • 12.Hater H, Halak M, Sunoqrot H, Khaitovich B, Raskin D, Silverberg D. Revascularization of multiple tibial arteries is not associated with improved limb salvage. J Vasc Surg 2021;74:170–7. [DOI] [PubMed] [Google Scholar]
  • 13.Yuo TH, Wallace JR, Fish L, Avgerinos ED, Leers SA, Al-Khoury GE, et al. Comparison of outcomes after open surgical and endovascular lower extremity revascularisation among end stage renal disease patients on dialysis. Eur J Vasc Endovasc Surg 2019;57:248–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Khan SZ, Dosluoglu HH. Should multiple vessels be recanalised for tissue loss irrespective of pedal anatomy and angiosome? Eur J Vasc Endovasc Surg 2018;55:528. [DOI] [PubMed] [Google Scholar]
  • 15.Cheng TW, Farber A, Kalish JA, King EG, Rybin D, Siracuse JJ. The effect of chronic and end-stage renal disease on long-term outcomes after infrainguinal bypass. Ann Vasc Surg 2023;94:129–35. [DOI] [PubMed] [Google Scholar]
  • 16.Levin SR, Farber A, Goodney PP, King EG, Eslami MH, Malas MB, et al. Five year survival in Medicare patients undergoing interventions for peripheral arterial disease: a retrospective cohort analysis of linked registry claims data. Eur J Vasc Endovasc Surg 2023;66:541–49. [DOI] [PubMed] [Google Scholar]
  • 17.Malas MB, Hamouda M, Farber A, Menard MT, Conte MS, Rosenfield K, et al. Outcomes of chronic limb-threatening ischemia revascularization in patients with chronic kidney disease in the BEST-CLI trial. J Vasc Surg 2025;81:945–56.e3. [DOI] [PubMed] [Google Scholar]
  • 18.Dilaver N, Twine CP, Bosanquet DC. Direct vs. Indirect angiosomal revascularisation of infrapopliteal arteries, an updated systematic review and meta-analysis. Eur J Vasc Endovasc Surg 2018;56:834–48. [DOI] [PubMed] [Google Scholar]
  • 19.Elbadawy A, Ali H, Saleh M, Hasaballah A. A prospective study to evaluate complete wound healing and limb salvage rates after angiosome targeted infrapopliteal balloon angioplasty in patients with critical limb ischaemia. Eur J Vasc Endovasc Surg 2018;55:392–7. [DOI] [PubMed] [Google Scholar]
  • 20.Bosanquet DC, Glasbey JC, Williams IM, Twine CP. Systematic review and meta-analysis of direct versus indirect angiosomal revascularisation of infrapopliteal arteries. Eur J Vasc Endovasc Surg 2014;48:88–97. [DOI] [PubMed] [Google Scholar]
  • 21.Varty K, Bolia A, Naylor AR, Bell PR, London NJ. Infrapopliteal percutaneous transluminal angioplasty: a safe and successful procedure. Eur J Vasc Endovasc Surg 1995;9:341–5. [DOI] [PubMed] [Google Scholar]

RESOURCES